Overview

Cost Effectiveness Of Linezolid In Central America

Status:
Withdrawn
Trial end date:
2011-03-01
Target enrollment:
0
Participant gender:
All
Summary
The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Linezolid
Criteria
Inclusion Criteria:

- Evidence of a legally acceptable representative signed and dated informed consent
document indicating that him or her has been informed of all pertinent aspects of the
study.

- Adult (18 years old or older) men and women with confirm diagnosis of VAP treated on
ICU with LIN or VAN; on the selected institutions.

Exclusion Criteria:

- Adult men or women with nosocomial pneumonia not associated to a ventilator.